Core Viewpoint - The company successfully held a special shareholders' meeting on February 24, where all proposed resolutions were approved, including a commercialization service agreement with Haisen Biopharmaceutical Co., Ltd. [1] Group 1: Shareholder Meeting Outcomes - The special shareholders' meeting confirmed the commercialization service agreement signed with Haisen Biopharmaceutical, which supports the company's future commercialization operations and business advancement [1] - The meeting also approved a reward scheme for the management team and adopted the 2026 share plan along with related authorization limits [1] Group 2: Strategic Partnerships - The company's wholly-owned subsidiary, Genting New Year Pharmaceutical Technology Co., Ltd., signed two strategic cooperation agreements with Haisen Biopharmaceutical, including a commercialization service agreement and a licensing agreement [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will provide commercialization services for six mature products under Haisen Biopharmaceutical, leveraging its existing sales and marketing system [2] - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in the Greater China region [1]
云顶新耀：公司股东特别大会通过商业化服务协议等决议案